High‐Risk Screening for Fabry Disease: Analysis by Tandem Mass Spectrometry of Globotriaosylceramide (Gb3) in Urine Collected on Filter Paper

Christiane Auray‐Blais1, Pamela Lavoie1, Michel Boutin1, Mona Abaoui1

1 Division of Medical Genetics, Department of Pediatrics, Faculty of Medicine and Health Sciences, Centre de recherche du CHUS, Université de Sherbrooke, Sherbrooke, Quebec
Publication Name:  Current Protocols in Human Genetics
Unit Number:  Unit 17.26
DOI:  10.1002/cphg.34
Online Posting Date:  April, 2017
GO TO THE FULL TEXT: PDF or HTML at Wiley Online Library

Abstract

Fabry disease is a complex, panethnic lysosomal storage disorder. It is characterized by the accumulation of glycosphingolipids in tissues, organs, the vascular endothelium, and biological fluids. The reported incidence in different populations is quite variable, ranging from 1:1400 to 1:117,000. Its complexity lies in the marked genotypic and phenotypic heterogeneity. Despite the fact that it is an X‐linked disease, more than 600 mutations affect both males and females. In fact, some females may be affected as severely as males. The purpose of this protocol is to focus on the high‐risk screening of patients who might have Fabry disease using a simple, rapid, non‐invasive high performance liquid chromatography‐tandem mass spectrometry (HPLC‐MS/MS) method for urinary globotriaosylceramide (Gb3) analysis. Urine filter paper samples are easily collected at home by patients and sent by regular mail. This method has been successfully used for high‐risk screening of patients with ophthalmologic manifestations and in an on‐going study for high‐risk screening of Fabry disease in patients with chronic kidney diseases. © 2017 by John Wiley & Sons, Inc.

Keywords: Fabry disease; filter paper sample; globotriaosylceramide (Gb3); high‐risk screening; mass spectrometry; urine

     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Table of Contents

  • Introduction
  • Basic Protocol 1: Analysis of Globotriaosylceramide in Urine Collected on Filter Paper by Tandem Mass Spectrometry
  • Support Protocol 1: Urine Collection on Filter Paper
  • Support Protocol 2: Preparation of Positive Quality Controls
  • Reagents and Solutions
  • Commentary
  • Literature Cited
  • Figures
  • Tables
     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Materials

Basic Protocol 1: Analysis of Globotriaosylceramide in Urine Collected on Filter Paper by Tandem Mass Spectrometry

  Materials
  • Healthy control urine sample (for the calibration curve)
  • Urine samples to be analyzed ( protocol 2)
  • Quality control samples ( protocol 3)
  • Gb 3 calibration curve working solutions:
    • STD I Gb 3 isoform working solution (see recipe)
    • STD II Gb 3 isoform working solution (see recipe)
  • C17‐Gb 3 internal standard working solution (1 µg/100 µl; see recipe)
  • Creatinine standard curve working solution (10 mM; see recipe)
  • Creatinine‐d 3 internal standard working solution (40 μg/100 μl; see recipe)
  • Methanol (MeOH), LC‐MS grade (EMD Millipore, cat. no. MX0486‐1)
  • Water (H 2O), LC‐MS grade (EMD Millipore, cat. no. WX0001‐1)
  • 99% formic acid (Thermo Fisher Scientific, cat. no. AC27048‐0010)
  • Ammonium acetate (Sigma‐Aldrich, cat. no. A1542)
  • Whatman‐GE 903 filter papers, 10 × 10 cm
  • Ultraviolet lamp
  • 5‐cm pneumatic punch (homemade or commercial equivalent)
  • Graphite pencil
  • Parafilm
  • 20‐ml clear borosilicate vials
  • Pasteur pipets (Ultident, cat. no. 170‐CTB700‐3)
  • 2‐ml vials, screw tread, 12 × 32 mm, clear glass (Chromspec, cat. no. C779100WM)
  • Screw cap 9 mm, preslit PTFE/silicone septum (Chromspec, cat. no. C779200XBBM)
  • Vortex
  • Quattro micro tandem quadrupole mass spectrometer equipped with an Alliance 2795 HPLC system with autosampler (Waters or equivalent system but the method must be optimized and validated on a case‐by‐case basis)
  • Zorbax Bonus‐RP Guard column cartridge (4.6 × 12.5 mm; Agilent Technologies)
  • MassLynx version 4.1 (Waters)
  • New Brunswick rotary shaker

Support Protocol 1: Urine Collection on Filter Paper

  Materials
  • 100 ml urine from an untreated Fabry female presenting a low level of Gb 3 (low quality control [LQC])
  • 100 ml urine from an untreated Fabry male presenting a high level of Gb 3 (high quality control [HQC])
  • 200, 5‐cm diameter filter paper disks (Whatman‐GE 903)
  • Magnetic stirrer and bar
  • Graphite pencil
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Figures

Videos

Literature Cited

Literature Cited
  Abaoui, M., Boutin, M., Lavoie, P., and Auray‐Blais, C. 2015. Tandem mass spectrometry multiplex analysis of methylated and non‐methylated urinary Gb3 isoforms in Fabry disease patients. Clin. Chim. Acta 452:191‐198. doi: 10.1016/j.cca.2015.11.018.
  Aerts, J.M., Groener, J.E., Kuiper, S., Donker‐Koopman, W.E., Strijland, A., Ottenhoff, R., van Roomen, C., Mirzaian, M., Wijburg, F.A., Linthorst, G.E., Vedder, A.C., Rombach, S.M., Cox‐Brinkman, J., Somerharju, P., Boot, R.G., Hollak, C.E., Brady, R.O., and Poorthuis, B.J. 2008. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc. Natl. Acad Sci. U.S.A. 105:2812‐2817. doi: 10.1073/pnas.0712309105.
  Allen, L.E., Cosgrave, E.M., Kersey, J.P., and Ramaswami, U. 2010. Fabry disease in children: Correlation between ocular manifestations, genotype and systemic clinical severity. Br. J. Ophthalmol. 94:1602‐1615. doi: 10.1136/bjo.2009.176651.
  Auray‐Blais, C. and Boutin, M. 2012b. Novel Gb3 isoforms detected in urine of Fabry disease patients: A metabolomic study. Curr. Med. Chem. 19:3241‐3252. doi: 10.2174/092986712800784739.
  Auray‐Blais, C., Giguère, R., and Lemieux, B. 2003. Newborn urine screening programme in the province of Quebec: An update of 30 years experience. J. Inherit. Metab. Dis. 26:393‐402. doi: 10.1023/A:1025115405074.
  Auray‐Blais, C., Cyr, D., Ntwari, A., West, M.L., Cox‐Brinkman, J., Bichet, D.G., Germain, D.P., Laframboise, R., Melançon, S.B., Stockley, T., Clarke, J.T., and Drouin, R. 2008. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Mol. Genet. Metab. 93:331‐340. doi: 10.1016/j.ymgme.2007.10.001.
  Auray‐Blais, C., Clarke, J.T.R., Young, S.P., Millington, D.S., and Schiffmann, R. 2009a. Proposed high‐risk screening protocol for Fabry disease in patients with renal and vascular disease. J. Inherit. Metab. Dis. 32:303‐308. doi: 10.1007/s10545‐009‐1055‐6.
  Auray‐Blais, C., Millington, D.S., Young, S.P., Clarke, J.T.R., and Schiffmann, R. 2009b. An efficient high‐risk screening protocol for Fabry disease. Mol. Genet. Metab. 96:S13. doi: 10.1016/j.ymgme.2008.11.008.
  Auray‐Blais, C., Boutin, M., Gagnon, R., Dupont, F.O., Lavoie, P., and Clarke, J.T.R. 2012a. Urinary globotriaosylsphingosine‐related biomarkers for Fabry disease targeted by metabolomics. Anal. Chem. 84:2745‐2753. doi: 10.1021/ac203433e.
  Auray‐Blais, C., Blais, C.M., Ramaswami, U., Boutin, M., Germain, D.P., Dyack, S., Bodamer, O., Pintos‐Morell, G., Clarke, J.T., Bichet, D.G., Warnock, D.G., Echevarria, L., West, M.L., and Lavoie, P. 2015. Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry. Clin. Chim. Acta 438:195‐204. doi: 10.1016/j.cca.2014.08.002.
  Boutin, M. and Auray‐Blais, C. 2015. Metabolomic discovery of novel urinary galabiosylceramide analogs as Fabry disease biomarkers. J. Am. Soc. Mass. Spectrom. 26:499‐510. doi: 10.1007/s13361‐014‐1060‐3.
  Clarke, J.T.R. 2007. Narrative review: Fabry disease. Ann. Intern. Med. 146:425‐433. doi: 10.7326/0003‐4819‐146‐6‐200703200‐00007.
  Dupont, F.O., Gagnon, R., Lavoie, P., and Auray‐Blais, C. 2012. A metabolomic study reveals novel plasma lyso‐Gb3 analogs as Fabry disease biomarkers. Curr. Med. Chem. 20:280‐288. doi: 10.2174/0929867311320020008.
  Germain, D.P. 2010. Fabry disease. Orphanet. J. Rare. Dis. 5:30. doi: 10.1186/1750‐1172‐5‐30.
  Lavoie, P., Boutin, M., and Auray‐Blais, C. 2013. Multiplex analysis of novel urinary lyso‐Gb3‐related biomarkers for Fabry disease by tandem mass spectrometry. Anal. Chem. 85:1743–1752. doi: 10.1021/ac303033v.
  Lin, H.Y., Chong, K.W., Hsu, J.H., Yu, H.C., Shih, C.C., Huang, C.H., Lin, S.J., Chen, C.H., Chiang, C.C., Ho, H.J., Lee, P.C., Kao, C.H., Cheng, K.H., Hsueh, C., and Niu, D.M. 2009. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ. Cardiovasc. Genet. 2:450‐456. doi: 10.1161/CIRCGENETICS.109.862920.
  Manwaring, V., Boutin, M., and Auray‐Blais, C. 2013. A metabolomic study to identify new globotriaosylceramide‐related biomarkers in the plasma of Fabry disease patients. Anal. Chem. 85:9039‐9048. doi: 10.1021/ac401542k.
  Meikle, P.J., Hopwood, J.J., Clague, A.E., and Carey, W.F. 1999. Prevalence of lysosomal storage disorders. JAMA 281:249‐254. doi: 10.1001/jama.281.3.249.
  Michaud, L. and Auray‐Blais, C., 2012. Improved ways to screen for patients with Fabry disease, involving optometry in a multidisciplinary approach. Can. J. Optometry 74:5‐32.
  Pisani, A., Visciano, B., Roux, G.D., Sabbatini, M., Porto, C., Parenti, G., and Imbriaco, M. 2012. Enzyme replacement therapy in patients with Fabry disease: State of the art and review of the literature. Mol. Genet. Metab. 107:267‐275. doi: 10.1016/j.ymgme.2012.08.003.
  Schiffmann, R., Waldek, S., Benigni, A., and Auray‐Blais, C. 2010. Biomarkers of Fabry disease nephropathy. Clin. J. Amer. Soc. Nephrol. 5:360‐364. doi: 10.2215/CJN.06090809.
  Thurberg, B.L., Rennke, H., Colvin, R.B., Dikman, S., Gordon, R.E., Collins, A.B., Desnick, R.J., and O'Callaghan, M. 2002. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int. 62:1933‐1946. doi: 10.1046/j.1523‐1755.2002.00675.x.
  Vedder, A.C., Linthorst, G.E., van Breemen, M.J., Groener, J.E., Bemelman, F.J., Strijland, A., Mannens, M.M., Aerts, J.M., and Hollak, C.E. 2007. The Dutch Fabry cohort: Diversity of clinical manifestations and Gb3 levels. J. Inherit. Metab. Dis. 30:68‐78. doi: 10.1007/s10545‐006‐0484‐8.
  Wang, R.Y., Lelis, A., Mirocha, J., and Wilcox, W.R. 2007. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet. Med. 9:34‐35. doi: 10.1097/GIM.0b013e31802d8321.
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library